From Our Partners
Monday, July 4, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

NIAID Partnerships for Biodefense Funding

by Global Biodefense Staff
March 5, 2013

In response to threats presented by bioterrorism and emerging infectious diseases, the National Institute of Allergy and Infectious Diseases (NIAID) is inviting research applications for projects focused on preclinical development of lead candidate therapeutics, vaccines, or medical diagnostics for select pathogens and toxins.

The funding announcement, released last week, places emphasis on biodefense detection technologies and therapeutics development that would improve vaccine effectiveness or simplify vaccine delivery to patient populations during a natural outbreak or intentional release of an infectious agent.

Examples of supported research areas may include: lead optimization; efficacy testing, safety evaluation; stability testing; manufacturing; adaptation of products or platform technologies to biodefense applications; development of broad spectrum platforms and/or production technologies; optimization of products or technologies; process development; scale-up; production of quantities sufficient for preclinical regulatory requirements; and diagnostic validation. Priority will be given to projects that address the greatest clinical need.

Development of safe and effective therapeutics against NIAID Category A, B, or C agents is a high priority. The NIAID funding effort will support immune-based and host-targeted therapeutics, with special interest in broad-spectrum therapeutics and those targeting antimicrobial-resistant pathogens and pathogens for which no standard clinical treatment exists. 

The Diagnostics for Biodefense portion of the effort supports development of diagnostics to rapidly identify select agents and their resistance profiles in diverse clinical samples from individuals at multiple stages of infection. Multiplexed diagnostics, as well as those able to provide diagnostic information on potential early, non-specific symptoms are particularly encouraged.

Diagnostic platform projects may include one or more of the following areas:

  • -Use of nanotechnology, microfluidic-based systems or any other novel or innovative system to process large numbers of patient samples
  • -Integrated sample-to-answer technologies for rapid, multiplexed antigen or other analyte detection using novel and improved sample processing and detection methods and reagents
  • -High throughput multiplex screening using analytes or signature biomarkers to identify human immune or other physiological response to infection
  • -Multiple methods for detection in the same platform, such as detecting nucleic acids, proteins and other targets from multiple agents in the same assay
  • -Resolving engineered or otherwise acquired genetic traits in microorganisms, such as patterns of microbial resistance or enhanced virulence
  • -High throughput, robotics, automated data output and analyses
  • -In vivo imaging methods and development of contrast reagents for visualization of pathogens or host immune responses in vivo

NIAID intends to commit $20 million in total costs in FY 2014 to fund 10 to 15 applications. Organizations eligible to apply include Higher Education Institutions, Nonprofits, Small Businesses and Other For-Profit Organizations, Government Organizations and Foreign Institutions.

Further details are available under RFA-AI-13-013. The application deadline is July 2, 2013. The earliest start date for funded work is May 2014.

From Our Partners
Tags: AntimicrobialsBiomarkersBioterrorismMultiplexNanotechVaccines

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research
Biodetection

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC